Protozoal pyrimidine biosynthesis enzyme

Protozoal pyrimidine biosynthesis enzymes represent a critical metabolic pathway in parasitic organisms such as Plasmodium, Leishmania, and Trypanosoma species. These enzymes facilitate the de novo synthesis of uridine monophosphate (UMP), a precursor for all pyrimidine nucleotides required for DNA and RNA replication (Cassera et al., 2011). Many protozoan parasites are obligate de novo synthesizers of pyrimidines, lacking the salvage pathways present in their human hosts, which makes these enzymes highly attractive targets for selective toxicity (Reis et al., 2017). The most prominent target within this group is dihydroorotate dehydrogenase (DHODH), which catalyzes the fourth step of the pathway and is linked to the mitochondrial electron transport chain (Müller et al., 2008). Inhibition of these enzymes, particularly by compounds like DSM265, leads to the cessation of parasite growth by starving the organism of essential genetic building blocks (Phillips et al., 2015). Therapeutic strategies focusing on this pathway aim to exploit structural differences between the parasite and human enzyme variants to ensure safety and efficacy in treating infections like malaria and leishmaniasis.

Other names

De novo pyrimidine biosynthesis pathwayProtozoan pyrimidine metabolic enzymesDihydroorotate dehydrogenase (DHODH)Orotate phosphoribosyltransferase (OPRT)Orotidine 5'-monophosphate decarboxylase (OMPDC)Carbamoyl phosphate synthetase II (CPSII)Aspartate transcarbamoylase (ATC)Dihydroorotase (DHO)

Inhibition of de novo pyrimidine biosynthesis leading to depletion of intracellular nucleotide pools and subsequent inhibition of DNA and RNA synthesis.